NCT05039190View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

September 25, 2021

Primary Completion Date

January 14, 2023

Study Completion Date

January 14, 2023

Conditions

Myasthenia Gravis

Interventions

DRUG

HBM9161 Injection (680mg)

HBM9161 Injection

DRUG

Placebo

Placebo Injection

Trial Locations (1)

Unknown

Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors

lead

Harbour BioMed (Guangzhou) Co. Ltd.

INDUSTRY

NCT05039190 - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients | Biotech Hunter | Biotech Hunter